• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A CBT App for Refractory Depression

A CBT App for Refractory Depression

July 1, 2018
Xiaofan Li, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Xiaofan Li, MD. Dr. Li has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Mantani A et al, J Medical Internet Res 2017;19(11):e373

Mobile phones have allowed the introduction of guided, self-help cognitive behavioral therapy (CBT) for depression with enhanced accessibility, efficiency, and affordability. Several meta-analyses suggest that computers can augment face-to-face psychotherapy and even work on their own through self-guided programs. Most of those studies involved patients with mild to moderate depression, which leaves open the question of how well this approach would work in more severe cases.

This study tested a self-guided mobile app in patients with moderate to severe depression who had not responded to at least 1 antidepressant trial. The Japanese app, called ­Kokoro, used cartoon characters to present concepts from CBT, including self-monitoring, behavioral activation, and cognitive restructuring.

The authors randomized 164 patients to an intervention group (medication switch plus Kokoro app) and control group (medication switch only). Although the treatments were not blinded, the outcomes were assessed with blinded raters.

After 9 weeks, the intervention group showed greater improvement in the Patient Health Questionnaire-9, the primary outcome measure (p < 0.001). Rates of remission (18% vs 10%) and response (32% vs 18%) were also greater, and the magnitude of the benefit compared favorably with the effect sizes seen in antidepressant ­trials.

In the second phase of the study, both groups were given access to the app for an additional 2 months. After that time, both groups had similar depression scores. The intervention group maintained their gains, and the control group caught up.

Most patients stayed engaged with the 8-session app, but that engagement was not entirely self-driven. Each week, participants received a brief, personalized email congratulating them on their progress.

TCPR’s Take
This study demonstrates significant benefits for this CBT app in difficult-to-treat depression. Its strengths include a randomized controlled design, blinded ratings, and high levels of engagement and completion. The main limitation is the lack of blinding in the treatment arm, which makes it difficult to rule out a placebo effect. By making changes to medications in both groups at the start of the trial, the authors attempted to minimize expectancy effects.

For clinicians, the main limitation may be the inaccessibility of the Japanese-language app, a common problem in this type of research. Most of the available mental health apps are untested, and most of the tested apps are not available. A reasonable substitute is Intellicare, a suite of CBT-based apps made free through NIMH funding. These apps looked promising in an uncontrolled study, and a large, randomized controlled trial of Intellicare is nearing completion (intellicare.cbits.northwestern.edu).
General Psychiatry
KEYWORDS research-update
Xiaofan Li, MD.

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2018
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Treatment-Resistant Depression, TCPR, July/August 2018
Welcoming Our New Editor-in-Chief
Seven Lifestyle Interventions for Treatment-Resistant Depression
A Primer on MAOIs
A CBT App for Refractory Depression
Treatment-Resistant Depression: Some Introductory Tips
Understanding Depressive Rumination
Antidepressant Augmentation Strategies: A Basic Guide
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.